We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Genetic Testing Benefits Postmenopausal Women with Breast Cancer

By LabMedica International staff writers
Posted on 26 Mar 2020
Print article
Image: Histopathology of cancerous breast tissue, the tumor cells have proliferated in a close pattern without tubular formation. This tumor represented moderately differentiated ductal carcinoma (Photo courtesy of The Japanese Society of Pathology).
Image: Histopathology of cancerous breast tissue, the tumor cells have proliferated in a close pattern without tubular formation. This tumor represented moderately differentiated ductal carcinoma (Photo courtesy of The Japanese Society of Pathology).
Germline genetic testing for pathogenic variants (PVs) in cancer susceptibility genes after breast cancer diagnosis may inform cancer treatment, prevention, and testing of relatives. Postmenopausal women with breast cancer had a threefold higher prevalence of pathogenic variants in breast cancer-associated genes than their cancer-free counterparts.

Whether testing should be performed depends partly on PV prevalence, which may be low in the general population but higher in women with risk factors (e.g., young diagnosis age, family history). For the best-characterized breast cancer susceptibility genes, BRCA1, BRCA2, or both (BRCA1/2), a minimum PV prevalence of 2.5% to 10% has been recommended for testing.

A team of medical scientists from Stanford University School of Medicine (Stanford, CA, USA) and their colleagues determine PV prevalence among women diagnosed with breast cancer after menopause versus the background prevalence among cancer-free postmenopausal women. The team analyzed data of women with banked DNA samples who participated in the Women’s Health Initiative, which enrolled more than 160,000 postmenopausal women aged 50 to 79 years between 1993 and 1998. They compared the prevalence of breast cancer-associated mutations in 10 genes, BRCA1, BRCA2, ATM, BARD1, CDH1, CHEK2, NBN, PALB2, STK11 and TP53, among 2,195 women diagnosed with breast cancer (median age at diagnosis, 73 years; 66.3% white) versus 2,322 women without breast cancer (median age at last follow-up, 81 years; 84.9% white).

The investigators reported that pathogenic variants were detected among 6.74% of women with breast cancer compared with 4.01% of women without breast cancer. Results showed pathogenic variants in one of the 10 breast cancer-associated genes among 3.55% of women with breast cancer compared with 1.29% of cancer-free women. Moreover, 2.21% of women diagnosed at younger than age 65 years carried BRCA1 or BRCA2 mutations compared with 1.09% of women diagnosed at age 65 years or older. Only 30.8% of women with breast cancer and 20% of women without breast cancer who carried BRCA1 or BRCA2 mutations appeared likely to have met current National Comprehensive Cancer Network guidelines for genetic testing.

Allison W. Kurian, MD, MSc, associate professor of medicine, and lead author of the study, said, “Although genetic testing is increasingly relevant for the care of patients with cancer, little was known about the prevalence of inherited mutations in cancer susceptibility genes among the most common group of women with breast cancer who are those diagnosed after menopause and without a strong family history of cancer.” The study was published on March 10, 2020 in the journal JAMA.

Related Links:
Stanford University School of Medicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.